FOR FURTHER INFORMATION CONTACT: Sidney A. Rosenzweig, Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436, telephone (202) 708-2532. Copies of non-confidential documents filed in connection with this investigation are or will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436, telephone (202) 205–2000. General information concerning the Commission may also be obtained by accessing its Internet server at *http://www.usitc.gov*. The public record for this investigation may be viewed on the Commission's electronic docket (EDIS) at http:// edis.usitc.gov. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on (202) 205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on March 7, 2011, based on a complaint filed by Graco Children's Products Inc. of Atlanta, Georgia ("Graco"). 76 FR 12368 (Mar. 7, 2011). The complaint named as the sole proposed respondent Baby Trend, Inc. of Ontario, California ("Baby Trend"), and alleged a violation of section 337 in the importation, sale for importation, and sale within the United States after importation of certain strollers and playards by reason of the infringement of certain claims of U.S. Patent Nos. 6,669,225; 7,044,497; 7,188,858; 7,404,569; and 6,510,570.

On January 6, 2012, Graco and Baby Trend jointly moved to terminate the investigation in its entirety on the basis of a settlement agreement. On January 18, 2012, the ALJ granted the motion as an ID. Order No. 11 at 2–3.

No petitions for review of the ID were filed. The Commission has determined not to review the ID.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in sections 210.21 and 210.42 of the Commission's Rules of Practice and Procedure (19 CFR 210.21, 210.42).

Issued: February 7, 2012. By order of the Commission.

### James R. Holbein,

Secretary to the Commission. [FR Doc. 2012–3212 Filed 2–10–12; 8:45 am] BILLING CODE 7020–02–P

# DEPARTMENT OF JUSTICE

#### **Drug Enforcement Administration**

#### Manufacturer of Controlled Substances; Notice of Registration

By Notice dated September 28, 2011, and published in the **Federal Register** on October 7, 2011, 76 FR 62450, Noramco, Inc., 500 Swedes Landing Road, Wilmington, Delaware 19801– 4417, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Drug	Schedule
Codeine-N-oxide (9053)	I
Dihydromorphine (9145)	I
Morphine-N-oxide (9307)	1
Amphetamine (1100)	II
Methylphenidate (1724)	II
Phenylacetone (8501)	II
Codeine (9050)	II
Dihydrocodeine (9120)	II
Oxycodone (9143)	II
Hydromorphone (9150)	II
Hydrocodone (9193)	II
Morphine (9300)	II
Oripavine (9330)	II
Thebaine (9333)	II
Opium extracts (9610)	П
Opium fluid extract (9620)	П
Opium tincture (9630)	П
Opium, powdered (9639)	II
Opium, granulated (9640)	П
Oxymorphone (9652)	II
Noroxymorphone (9668)	Ш
Tapentadol (9780)	II

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Noramco, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Noramco, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: February 1, 2012. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2012–3268 Filed 2–10–12; 8:45 am] BILLING CODE 4410–09–P

## DEPARTMENT OF LABOR

# Employment and Training Administration

# Notice of a Change in Status of an Extended Benefit (EB) Period for Alaska

**AGENCY:** Employment and Training Administration, Labor. **ACTION:** Notice.

**SUMMARY:** This notice announces a change in benefit period eligibility under the EB program for Alaska.

The following changes have occurred since the publication of the last notice regarding the State's EB status:

• Alaska's 13-week insured unemployment rate (IUR) for the week ending January 7, 2012 rose to meet the 6% threshold to trigger "on" to the EB program. Alaska's payable period in the Extended Benefits program began January 22, 2012.

The trigger notice covering state eligibility for the EB program can be found at: *http://ows.doleta.gov/ unemploy/claims arch.asp.* 

#### **Information for Claimants**

The duration of benefits payable in the EB program, and the terms and conditions on which they are payable, are governed by the Federal-State Extended Unemployment Compensation Act of 1970, as amended, and the operating instructions issued to the states by the U.S. Department of Labor. In the case of a state beginning an EB period, the State Workforce Agency will furnish a written notice of potential entitlement to each individual who has exhausted all rights to regular benefits and is potentially eligible for EB (20 CFR 615.13(c)(1)).

Persons who believe they may be entitled to EB, or who wish to inquire about their rights under the program, should contact their State Workforce Agency.

FOR FURTHER INFORMATION CONTACT:

Scott Gibbons, U.S. Department of Labor, Employment and Training Administration, Office of Unemployment Insurance, 200 Constitution Avenue NW., Frances Perkins Bldg. Room S–4524, Washington, DC 20210, telephone